hCD5 Mouse

CD5 (Cluster of Differentiation 5) is a type I transmembrane glycoprotein belonging to the scavenger receptor cysteine-rich (SRCR) superfamily. It is primarily expressed on the surface of T cells and a subset of B cells. In T-cell malignancies, CD5 has emerged as an important target for emerging immunotherapeutic approaches, including CAR-T cells, CAR-γδT cells, and NK cell engagers (NKCEs) ^[1-2]. In addition, the involvement of CD5 in immune tolerance, inflammatory regulation, and tumor immune microenvironment modulation makes it an important target for basic immunology and immune regulatory mechanism studies ^[3].

hCD5 mice were generated using gene editing technology, in which the partial sequence of exon 2 and partial sequence of intron 2 of the mouse Cd5 gene were replaced with the Chimeric human CD5 CDS-3'UTR of mouse Cd5-WPRE-BGH pA cassette. The signal peptide-encoding sequence of the mouse Cd5 gene was retained. hCD5 mice are mainly used for cancer immunotherapy and autoimmune disease research. This model can be applied to evaluate the in vivo efficacy of anti-human CD5 antibodies and other CD5-targeted therapeutic strategies, support mechanism studies of T-cell malignancies, and facilitate the development and evaluation of emerging immunotherapeutic approaches, including CAR-T cells, CAR-γδT cells, and NK cell engagers (NKCEs). Furthermore, this model can be used to investigate the roles of CD5 in T-cell activation, immune tolerance, inflammatory responses, and tumor immune microenvironment regulation, as well as to support studies of immune-modulatory therapeutic strategies for autoimmune diseases.